There’s no better due diligence in the psychoactive drug space than Health Canada. Loads of pharma companies have investor decks that promise they’ll one day be in the psychedelics…
Ibogaine
Back in October, Zuckerberg, seeing plunging user numbers and fading growth, desperately renamed Facebook, once the world’s foremost purveyor of misinformation and unethical aggregator of personal data, to Meta,…
Environmental, Social and Governance (ESG) focused investment is a relatively new accepted method for socially conscious investors to allocate their investment capital in public/private companies that align with their…
Health Canada stepped up to the plate back in December with a Notice of Intent to amend the Food and Drug Regulations and the Narcotic Control Regulations to restore…
The Bare Naked Ladies made “if I had a million dollars,” famous, as they tunefully explained what they would do with their riches. However, in the post-crisis everything bubble,…
Psychedelics have showed tremendous potential in treating neurological conditions such as major depressive disorder, PTSD, ALS, and generalized anxiety. Investors jumped on the opportunity, sending market values skyrocketing. It’s…
The world’s first psychedelic ETF, PSYK, is an industry bellwether which indicates the psychedelics space continues to take a drubbing since the ETF launched in January. The fund closed…
The psychedelics space is loaded with over-valued unicorns and also-rans, making it difficult for investors to find real growth opportunities. Here are some companies in the sector that have…
In this episode, we take a look at 3 Canadian psychedelic stocks with potential: MYND Life Science (MYND.C), Mind Cure Health Inc. (MCUR.C), NeonMind Biosciences (NEON.C). We briefly go…
Whether you’re curious about taking a psychedelics investment trip or a tie-dyed-in-the-wool public market backer, psychedelics conferences are the best way to keep on top of industry advances and…